Medical consequences of doping with anabolic androgenic steroids (AAS): effects on reproductive functions.

Eberhard Nieschlag$^{1,2}$ and Elena Vorona$^3$

$^1$Centre of Reproductive Medicine and Andrology
University of Münster, Münster, Germany

$^2$Center of Excellence in Genomic Medicine Research
King Abdulaziz University, Jeddah, Saudi Arabia

$^3$Centre of Endocrinology, Diabetology and Rheumatology, Dortmund, Germany

Correspondence should be addressed to E. Nieschlag,
Email: eberhard.nieschlag@ukmuenster.de

Abstract

Anabolic androgenic steroids (AAS) are the favoured appearance and performance enhancing drugs (APED) used in competitive athletics, in recreational sports and by body-builders. The global lifetime prevalence of AAS abuse is 6.4% for males and 1.6% for women. Many AAS, often obtained from the internet and dubious sources, have not undergone proper testing and are consumed at extremely high doses and in irrational combinations, also along with other drugs. Controlled clinical trials investigating undesired side-effects are lacking since ethical restrictions prevent exposing volunteers to potentially toxic regimens, obscuring a causal relationship between AAS abuse and possible
sequelae. Because of the negative feedback in the regulation of the hypothalamic-pituitary-gonadal axis, in men AAS cause reversible suppression of spermatogenesis, testicular atrophy, infertility and erectile dysfunction (anabolic steroid induced hypogonadism). Should spermatogenesis not recover after AAS abuse, a pre-existing fertility disorder may have resurfaced. AAS frequently cause gynecomastia and acne. In women, AAS may disrupt ovarian function. Chronic strenuous physical activity leads to menstrual irregularities and, in severe cases, to the female athlete triad (low energy intake, menstrual disorders and low bone mass), making it difficult to disentangle effects of sports and AAS. Acne, hirsutism and (irreversible) deepening of the voice are further consequences of AAS misuse. There is no evidence that AAS cause breast carcinoma. Detecting AAS misuse through the control network of the World Anti-Doping Agency (WADA) not only aims to guarantee fair conditions for athletes, but also to protect them from medical sequelae of AAS abuse.

**Introduction**

Medal-winning athletes are the undisputed icons of society. As role models they are also expected to show impeccable character and behaviour. Society rewards them with admiration and dedication, in no way objecting to exorbitant financial gains by their idols; governments and companies consider athletes’ triumphs as advertisements for their politics and products respectively. In addition to exhaustive training, this places athletes under tremendous pressure, not only to excel in their discipline, but also to
resist the temptation to use any illicit means, e.g. drugs, to enhance performance. “Play true” is the motto of the World Anti-Doping Agency (WADA), appealing to all athletes to refrain from using illicit drugs, but without the elaborate worldwide network of doping controls and sanctions against doping (www.wada-ama.org,1,2), WADA’s call for fairness would remain without echo. However, doping is not reserved for the small squad of elite athletes, it has spread from the idols at the top to all rank and file participants in sports, from adolescents to seniors. The global lifetime prevalence rate of using AAS is 6.4% for males and 1.6% for females (3). Not only classical sport disciplines are involved, the phenomenon is similarly widespread among bodybuilders, so that the drugs used have been collectively classified as “appearance and performance enhancing drugs” (APEDs) and summarized in the WADA Prohibited List 2015(www.wada-ama.org).

Although doping has been practiced since antiquity, often with placebo or toxic effects, really effective APEDs only became available with the rise of modern pharmacology, and in particular, following the isolation and synthesis of testosterone and anabolic androgenic steroids (AAS). Testosterone came into clinical use shortly after its synthesis in 1935 (4) and its first documented use for doping was by German rowers in 1952 (to maintain their marital duties during exhausting training) and by Russian weight lifters in 1954 to enhance their power. Since then AAS lead the lists of APEDs worldwide and among these testosterone is used in almost 50%, be it in the 4500 doping-positive samples collected by WADA worldwide in 2012 (5) or be it among black market substances confiscated by customs and police (6) (Table 1).
As all licensed testosterone and AAS preparations are available only by prescription, the drug sources remain obscure. In part, these substances are no longer or have never been on the open market. There have been instances of doctors prescribing AAS especially under pressure of bodybuilders, who undertake any risk to become champions. Surveys among fitness center clientele revealed that up to half of APED users obtained the drugs with or without prescription from physicians or pharmacies (7,8). Labs in Eastern Europe, Asia and South America producing multitudes of AAS offer them for sale on the internet which, next to gyms and fitness studios, has become the major source of AAS. When counted in November 2011 there were 328,000 internet pages accessible under the search term “steroids for sale” (9)! Furthermore, AAS may be added to food supplements – often undeclared on the label (10,11,12) or found in phytopharmaka and animal organ extracts. For example, musk pods used in Chinese traditional medicine contain 16 different, undeclared AAS, as discovered in doping controls (13). Finally, secret but official programs of sport organisations or states may provide AAS and other APEDs to their athletes, as demonstrated by the systematic doping program of the former German Democratic Republic (GDR) in the 1970s and 1980s which became evident after the collapse of that régime in 1989 (14).

AAS – as all other APEDs – may not only have the desired, but also adverse side effects, resulting from the combination of different AAS in extremely high doses with other drugs and from duration of administration over periods ranging from months to many years. Due to the secret nature of this drug abuse type, doses and duration are mostly unknown and properly controlled clinical trials do not exist. Hence the
scientific assessment of the sequelae of AAS abuse relies on case reports and on a few retrospective investigations, making a review of the field in the age of evidence-based medicine extremely difficult and frustrating. Nevertheless, this review is intended to inform the endocrinologist about symptoms and diseases caused by AAS which, without specific knowledge, may be misinterpreted while searching for their origin. Proper diagnosis is further hindered by the reluctance of the doped patient to admit consumption of AAS and ignorance about their possible serious side effects.

This review highlights the effects of testosterone and AAS on male and female reproductive functions and includes effects on the skin and its appendices as secondary sexual characteristics (overview in Table 2). For adverse effects on other organ systems the reader is referred to previous reviews (e.g. 15-19). For the sake of manageability testosterone and AAS (including designer steroids) are referred to collectively as AAS, although both chemical structure and biological profiles of individual AAS differ. In general, the effects and side-effects of specific AAS depend on their chemical structure. The full spectrum of biological action requires that the androgen can be aromatized to estradiol as well as reduced to 5alpha-dihydrotestosterone. As indicated in Figure 1, the most frequently used AAS, testosterone, boldenone, metandione and nortestosterone can be aromatized as well as 5alpha-reduced, while fluoxymesterone and formebolone can be 5alpha-reduced but not aromatized, and some AAS can be neither aromatized nor 5alpha-reduced, especially those that are dihydrotestosterone derivatives (Figure 1). In addition, the genetic disposition of the individual athlete may modify the reaction to androgenic substances, as exemplified by the androgen receptor polymorphism modulating
testosterone activity (20). However keeping these apart is difficult due to the varying combinations and doses in addition to the often practiced doping polypharmacy (21, 22) including erythropoietin, insulin, IGF-1, thyroxine, clenbuterol, amphetamines, diuretics, etc. However, the unique common feature of alkylation in the 17α-position of the androgen molecule should be pointed out since these AAS are potentially severely liver toxic (Figure 1). AAS abuse is also characterized by “stacking and cycles” i.e. increasing doses over time and changing preparations and their combinations alternating with AAS-free periods in order to maximize desired effects and minimize side-effects. Whether these regimens indeed fulfill their purpose cannot be assessed as they are based on trial and error and appropriate studies do not exist.

Effects of AAS on male reproductive functions

Suppression of spermatogenesis

As endogenous testosterone is the major regulator of the hypothalamo-pituitary-testicular axis, it is not surprising that exogenous testosterone and AAS exert a suppressive effect on the hypothalamo-pituitary system. The resulting suppression of LH and FSH leads to a decrease in intratesticular testosterone and secreted testosterone, as well as to a decrease in spermatogenesis and sperm production. This effect forms the basis for clinical trials in hormonal male contraception. As there are no systematic investigations of the effects of doping with high-dose AAS on testicular function, contraceptive trials may serve as a model for what happens under AAS suppression.
Male hormonal contraceptive trials use testosterone alone in therapeutic doses or in combination with gestagens to induce azoospermia or severe oligozoospermia compatible with contraceptive protection (for review 23). Testosterone derivatives used for doping such as 19-nortestosterone and MENT have also been applied in contraceptive trials (24,25). The kinetics of sperm suppression and recovery are quite well known from these carefully conducted trials using therapeutic doses (26,27). Of 1549 healthy eugonadal men participating in 30 different clinical trials, after cessation of medication, 67% showed a return to sperm concentrations above 20 mill/ml within 6 months, 90% within 12 months, 96% within 16 months and 100% within 24 months (26). While the different regimens used in the 30 trials were not identical, they used similar steroid doses and the differences in recovery time appear to be determined more by characteristics of the individual than by the therapeutic regimen. Nevertheless, all men returned to fertile levels of sperm counts. Thus a 6–24 month span provides a time frame for recovery in AAS abusers, although it has to be kept in mind that doses used for doping far exceed those used for male contraception, and therefore even longer periods may be anticipated.

These results may help to interpret case reports and small retrospective studies in AAS abusers. These show a wide spectrum of sperm counts in AAS users under treatment, as well as after cessation of abuse ranging from normal levels to azoospermia. (Fig. 2) (28,29). LH and FSH correlate grossly with sperm counts, i.e. the lower the gonadotropins, the lower the sperm counts tend to be. Parallel to the decline in
spermatogenesis, testicular volumes decrease significantly since the tubules occupy about 95% of the testes volume and their atrophy causes shrinkage of the testes. Varying doses, preparations and combinations of AAS and other APED make it difficult to draw general conclusions from individual observations, but it is clear that the recovery of sperm counts correlates positively with duration of time since last intake of AAS, as do sperm morphology and motility (Figure 2). As AAS may be abused for many years at high doses and in varying combinations, it is impossible to predict their impact on spermatogenesis without proper investigations.

In some AAS abusers recovery may take irritatingly long. This, in addition to individual predisposition, is most likely due to the depot effects of the huge steroid concentrations consumed (30,31). For example, after termination of nandrolone abuse metabolites could still be detected in urine after more than a year in some men (32). In other candidates sperm counts may not reach the normal range after cessation of doping, possibly due to preexisting fertility problems. When infertile men with subnormal sperm counts were included in a contraceptive trial using testosterone undecanoate alone, all returned to their (subnormal) baseline levels after cessation of testosterone undecanoate administration, but did not become better or worse than before the trial (33). In analogy, those AAS users who apparently do not return to normal sperm counts may never have had normal values before initiation of AAS abuse.
In conclusion, to date there is no indication that AAS abuse causes permanent damage to spermatogenesis, although suppression may cause transient azoospermia and recovery may take up to two years. However, no systematic investigations exist to provide a definitive answer.

Considering the great number of teenage boys using AAS, the question arises whether their use by boys around puberty may be harmful to spermatogenesis. Although systematic investigations in pubertal AAS users are lacking, treatment of over-tall boys with high doses of testosterone - close to doping doses - for reduction of final height provides an analogy. Initially it was suspected that this treatment would be harmful to the testes and leave permanent damage. However, when the proper control groups were co-investigated, the incidence of subnormal semen parameters was the same in both groups (34,35), indicating that at this age the testes do not differ from adult men in their capacity to recover from suppression.

Testicular tumours

In connection with AAS abuse, testicular germ cell tumours have not been reported in the literature. A single case of a leiomyosarcoma in a former GDR weightlifter has been reported. He used oralturinabol at high doses (up to 20 tablets per day) from 18 to 23 years of age. He developed gynaecomastia under the treatment and was, at the age of 32, operated for a unilateral intratesticular leiomyosarcoma (36). As these tumours are extremely rare and have been described in hamsters after treatment with testosterone propionate and diethylstilbestrol (37), the authors suspected a causal
relationship between AAS abuse and the sarcoma. As this remains the only reported case, possible involvement of AAS in the pathogenesis of the tumour remains unclear.

Hypogonadism induced by anabolic steroids

In addition to decreased sperm counts and testes volumes, some AAS abusers experience lack of libido and erectile function as well as other signs of hypogonadism. This occurs especially in those men abusing aromatizable AAS, resulting in high estrogen levels. Although physiological levels of estrogens are necessary for normal sexual function (38), the extremely high doses and the imbalance between testosterone and estradiol appear to be the cause of sexual dysfunction in these cases. This may also occur during the recovery phase after termination of exogenous AAS supply, when endogenous production has not yet resumed full activity. This type of hypogonadism (31) has been referred to as “anabolic steroid induced hypogonadotropic hypogonadism” (39 and more recently, simply as “anabolic steroid induced hypogonadism” (ASIH) (40, 41). In a large US urology department, 96 of 6033 (=1.6%) patients consulting for hypogonadism suffered from ASIH. One quarter of these patients presented with infertility and three quarters with sequelae of hypogonadism (41). Many of these AAS abusers were first overlooked and only diagnosed after renewed interviewing following inconclusive investigations. This reflects the fact that patients seeking medical care only reluctantly admit to AAS abuse and targeting AAS abuse directly should be part of the routine work-up of hypogonadal men (17).
Cessation of AAS abuse is the prime measure to treat ASIH. In addition, various therapeutic attempts have been undertaken to overcome ASIH and to hasten recovery. hCG has been given in individual cases (42), and has also been combined with tamoxifen or clomiphene to counteract the increased estrogen levels under hCG, inducing or worsening gynecomastia (43, 44). However, in power athletes administering hCG simultaneously with AAS in order to maintain fertility, an increase in morphologically abnormal sperm was observed in comparison to a control group receiving only AAS. This may be due to the lack of FSH under stimulation by hCG alone (45). So, although sperm counts were maintained under this treatment, fertility may still be compromised due to deteriorated sperm morphology. In cases with erectile dysfunction PDE-5-inhibitors have been prescribed but again, no systematic studies exist.

The continuing lack of conclusive studies prevents clear recommendations on how to treat ASIH except to stop AAS and other drug intake immediately and to await recovery in patience. It also remains ethically questionable whether the consequences of hormone abuse should be counteracted by additional hormone treatment, when normal conditions can be reconstituted by strict termination of abuse and waiting for spontaneous recovery. Only if no improvement has been observed within 24 months may gonadotropin treatment be justified (30,46).

**Prostate**

Prostate development and growth is dependent on androgens (47). The prostate grows during puberty and the small prostates of hypogonadal patients attain normal adult
dimensions under testosterone treatment. Furthermore, androgens are often considered
promoters or even initiators of prostate carcinoma so that one would expect a high rate
of benign prostatic hypertrophy and prostate carcinoma in AAS abusers, often exposed
to high doses of various AAS. Despite these considerations only one case has been
reported of a bodybuilder who used combinations of different oral and injectable AAS
at high doses over a time span of 18 years, occasionally augmented by growth
hormone injections, who developed an adenocarcinoma of the prostate at age 40 (48).
Considering this drug anamnesis it is tempting to suspect a causal relationship, but the
lack of further case reports or systematic investigations do not support this suspicion
(49). The observation that the type and duration of sport activities may influence the
occurrence of prostate carcinoma (as well as erectile dysfunction and infertility) makes
interpretation of AAS abuse even more difficult. In cyclists over 50 years of age a
clear positive correlation between the incidence of prostate cancer and hours of weekly
cycling time (<3.75 to >8.5 hours/week) was found (50). Furthermore, the observation
that hypogonadal men treated with therapeutic doses of testosterone do not suffer from
a higher incidence of prostate carcinoma than patients not treated with testosterone
(51), supports the hypothesis that prostate carcinoma develop independently of
possible androgen treatment.

Similarly, there are no clear indications, case reports or systematic investigations
demonstrating that AAS abuse causes benign prostatic hypertrophy (BPH). As shown
in the preclinical model of the cynomolgus monkey, co-administration of testosterone
and norethisterone prevents the testosterone-induced prostate growth and hypertrophy
(52). As several AAS also have gestagenic activity in addition to androgenic effects,
some AAS may prevent testosterone-dependent prostate growth when given in combination and this may explain the low incidence of BPH in AAS abusers.

**Effects of AAS in women**

**Reproductive functions**

In females delayed menarche, dysmenorrhoea, oligomenorrhoea, secondary amenorrhoea, anovulation and, as their consequence, infertility are the changes most often attributed to AAS abuse. However, physical and athletic activity often result in reproductive disregularities due to disruption of the GnRH pulse generator at the hypothalamic level. This leads to a decrease in LH and FSH and thus to decreased estrogen production (53,54) A population-based survey among 3,887 Norwegian women revealed that those who were physically active on most days were 3.2 times more likely to have fertility problems than inactive women. Exercising to exhaustion caused a further increase in fertility problems. However, after terminating the active sport, the number of nulliparous women was the same in the inactive and formerly active women (55). When the influence of physical activity in 2,232 women undergoing IVF treatment was investigated, those women who exercised 4 or more hours per week for 1-9 years were 40% less likely to experience a live birth in the first IVF cycle than those who did not exercise at all (56). Among 717 of 849 elite female athletes participating in the 2011 IAAF Championship using neither hormonal contraceptives nor AAS, 168 were oligo- or amenorrhoic. Only 5 of the 849 women were identified as AAS abusers (57). This indicates that ovulation and menstrual disorders leading to infertility are common among physically active women and especially among competitive athletes, even without AAS abuse.
Furthermore, the type of sport and the body composition required influence reproductive functions. Ballet dancers and competitive gymnasts start strenuous training at an early age and retain a lean physique with extremely low fat mass. Consequently, their menarche occurs two years later than in less active girls. In runners, menstrual disorders occur in 25% on average, with frequency correlating positively with distances covered per week. Swimmers have fewer irregularities than other athletes, probably due to their higher estrogen-generating fat mass than other sportswomen (for review 53,58). The lack of estrogens may become so severe that the syndrome of the “female athlete triad” (disturbed energy balance due to disturbed eating behaviour, menstrual irregularities and low bone mineral density) has been identified as a severe consequence of intensive sport activity (59,60). The high frequency of reproductive anomalies among female athletes highlights the difficulty in disentangling effects of exhausting sport activities and of AAS abuse in the absence of controlled studies and only few case reports. In cases of the female athlete triad, it has been speculated that (moderate) AAS intake could prevent some of the symptoms.

To approach the possible influence of androgens on the female organism, investigations on the therapeutic use of testosterone in women may be consulted. A large investigation with the aim of evaluating the side-effects of testosterone administration in therapeutic doses in women showed no significant differences concerning frequency of cerebrovascular diseases, coronary heart disease, breast carcinoma, deep venous thrombosis/lung embolism, diabetes mellitus or acute hepatitis between women receiving testosterone therapy and the control group (61,62).
If changes of the reproductive system due to suppression of the hypothalamic-pituitary-gonadal axis, such as dysmenorrhoea, secondary amenorrhoea with anovulation, or reduction of breast size are attributed to AAS abuse, they should also be reversible if caused by AAS. It can take weeks or months up to complete recovery of the axis. In some cases it has been reported that after cessation of AAS administration in women it took up to 20 months until testosterone concentrations in serum dropped to normal levels (62), correlating with observations on spermatogenesis in male AAS abusers (see above). Concerning possibly irreversible side-effects of AAS use in women, such as clitoris hypertrophy, no well-documented case reports or studies are available.

**Hirsutism and alopecia**

Hirsutism and alopecia are frequent, but in most instances reversible side-effects of androgen and AAS use in women (64,65). Assessment of body hair and hirsutism has to take ethnic dispositions into account. The degree of increased facial or body hair growth depends on dose and duration of AAS abuse and can be described according to the hirsutism score by Ferriman-Gallwey, established in 1961. Based on the intensity of hair growth in nine face/body areas, hirsutism can be diagnosed as mild, moderate or severe (66). However, proper analysis of the grade of hirsutism and alopecia in AAS abusers has not been undertaken.

**Deepening of the voice**
Lowering of the voice is caused by growth of the larynx in girls and by thickening of
the vocal chords in women after puberty and can be monitored objectively. As
laryngeal tissue has androgen receptors, the voice is part of the virilization that
androgenic substances and AAS can cause in women. The voice is an important
phenotypic characteristic of a person’s identity and changes are easily recognized
during social contacts. The voice change can be so pronounced that on the telephone
women may be mistaken for men. It is accompanied by hoarseness which may
intensify upon longer use of the voice. This dysphonia may become a problem for
teachers, actors and singers who are professionally dependent on their voices.

Such voice alterations are observed with endogenous elevation of testosterone levels
e.g. congenital adrenal hyperplasia (67) or in women sensitive to the androgenic action
of some oral contraceptives. Effects of androgens prescribed for other than doping
purposes in women (endometriosis, climacteric complaints, low libido, cellulitis etc.)
have been described in some detail (68-70). In low-dose transdermal testosterone trials
12/545 postmenopausal women receiving placebo and 15/545 on placebo reported
voice changes (64), emphasising the importance of controlled studies when evaluating
subjective parameters.

In contrast to acne, hirsutism, alopecia and mammary atrophy, deepening of the voice
due to AAS tends to be irreversible. However, although deepening of the female voice
is mentioned in all pertinent reviews dealing with AAS abuse, it is surprising that no
systematic investigations exist, and even case reports are very rare. Most information
is anecdotal and some comes from telephone interviews or hotlines. For example 11% of 217 women consulting the anti-doping hotline of a Swedish university hospital complained of hoarseness or lowering of the voice (71); however, as only those with complaints use such hotlines, the figures are not representative. As changes of the voice are mostly irreversible, androgen application must be suspended at the earliest sign of symptoms, if they are to be avoided.

The risk of breast cancer

Breast cancer is the most frequent carcinoma in women with 96 new cases per 100,000 women and year in Western Europe (72). This high prevalence has to be kept in mind when considering any additional changes in AAS abusers. The effect of exogenous androgens on the development of breast cancer has been discussed controversially in the scientific literature. The lack of controlled studies and epidemiologic investigations contributes to the uncertainties so that indirect evidence from other clinical situations has to be referred to.

In premenopausal women – the group to which most AAS abusers belong – most studies do not demonstrate an association between serum testosterone levels and breast cancer risk (62). In postmenopausal women, however, a small increase in the risk for breast cancer in correlation to testosterone and androstenedione serum levels was found, but only in E+/P+ cancers (73).

In recent years low-dose testosterone – mainly transdermal – has been used for the
treatment of female sexual dysfunction, in particular of hypoactive sexual desire syndrome (HSDD). In this context the risk of breast cancer has become a concern. Recent reviews (62,74) and practice guidelines (75) find no evidence for an increased risk, but also conclude that no RCT has been of sufficient size or duration to provide a definitive answer to the impact of testosterone on breast cancer risk.

Experience with long-term hormonal therapy in transsexuals (female-to-male) aiming at virilization (standard therapy: testosterone enanthate 250 mg i.m. every second week or testosterone undecanoate 1000 mg every 10-12 weeks for 2-3 years before surgical therapy e.g. mastectomy, ovar- and hysterectomy, and for years after that) shows no increased risk for breast cancer (78,77). Since the 1970s, when hormonal therapy of transsexuals was first documented, only one clinical case has been reported; in this case a mamma carcinoma of the residual breast tissue developed 10 years after bilateral mastectomy and continuous testosterone therapy (78).

The polycystic ovary syndrome (PCOS) is characterized by a significant increase of the testosterone concentration in blood and often serves as a model for long-term testosterone exposure in women. Studies showed that the risk for breast cancer in these women does not increase (79).

Exogenous androgens are partially metabolized to estrogens in breast tissue. However, not all synthetic androgens are subject to aromatization, e.g. tibolone and its metabolites cannot be aromatized (80). This also applies to the metabolism of oral turinabol (chlordehydromethyltestosterone) predominantly used in the former
GDR. Unless taken at extremely high doses, the molecule is not aromatized, so that estrogenic side-effects become clinically irrelevant (81).

A large randomized study showed that postmenopausal women receiving estrogens exclusively did not have an increased risk of mammary carcinoma, in contrast to women who received an estrogen/gestagen combination (82). The age of the patient and the duration of estrogen therapy are considered as risk factors for the development of breast cancer in women. Comparable results have also been shown in other studies (83,84). However, women who received hormone replacement therapy (estrogen or estrogen/gestagen preparations) at the time point of the evaluation, in comparison to those who had never taken hormonal drugs, had a higher risk for development of breast cancer. Women who in the past had received hormonal therapy did not have a higher risk for mamma carcinoma.

It has also been shown that additional administration of testosterone during hormonal replacement therapy in postmenopausal women (estrogen-gestagen preparations) inhibited proliferation of breast cells and thereby decreased the risk of mammary carcinoma (85). A recent 5-year interim analysis of a 10-year prospective study demonstrated that in women treated with testosterone implants the incidence of breast cancer was significantly reduced compared to untreated women (86).

In vitro, in animals and also in postmenopausal patients androgens (e.g. testosterone, DHT) blocked proliferation of breast cells caused by estrogens as well as expression of estrogen receptor genes (87-91). The antiproliferative and proapoptotic action of
androgens is probably mediated through the androgen receptor, despite the potential of testosterone to metabolize to estrogens (79). Before these interrelations were known, advanced stages of mamma carcinoma had even been treated with testosterone from the 1940s until the 1970s (90). The underlying clinical experience was that testosterone inhibits rather than supports a breast carcinoma. A genetic disposition concerning mutations in BRCA1- and BRCA2-genes (breast cancer gene) can exhibit a higher risk for the development of a breast carcinoma.

In conclusion, there are no appropriate epidemiologic studies which clearly document or negate a causal connection between the administration of AAS in young female athletes and the development of breast carcinoma later in life. Nor is there an accumulation of case reports which would argue for such a connection. Indirectly it can be assumed that use of AAS at young ages cannot be causal for breast cancer. However, as in the case of clinical low-dose testosterone treatment, sufficiently powered epidemiologic studies are required to provide a definitive answer concerning the breast cancer risk in AAS abusers.

**Side-effects of AAS on the skin in both sexes**

The use of AAS can very rapidly lead to cutaneous changes in previously unaffected athletes so that the dermatologist may be among the first physicians to be confronted with AAS abuse. AAS act through the androgen receptor, presenting in epidermal and follicular keratinocytes, sebocytes, sweat gland cells, dermal papilla cells, dermal fibroblasts, endothelial cells, and genital melanocytes. The effects are mediated through affection of the sebaceous gland growth and differentiation, hair growth,
epidermal barrier homeostasis and wound healing (93). The AR polymorphism appears to play a role in the severity of symptoms (93).

The most frequent skin manifestations are acne vulgaris, oily skin, seborrhoea, striae, hirsutism and male pattern alopecia (64). The incidence of acne in AAS abusers ranges from 17% in persons consulting a Swedish anti-doping hotline (71) to over 50% of athletes taking part in a questionnaire aiming to identify unsupervised AAS regimens and side-effects of AAS (94). After elimination of the causal agent these changes are mostly reversible. To speed up recovery, anti-androgen therapy with cyproterone acetate or spironolactone may be tried (93). However, severe forms of AAS-induced acne conglobata will leave extensive scarring on the affected skin areas (95).

After acne, striae distensae as a result of rapid muscular hypertrophy, supported by AAS intake, is the most prevalent skin side-effect in athletes, especially in bodybuilders. Over 40% of athletes complained about stretch marks of the skin (96) with typical localisation in the musculus pectoralis or upper arm region. After discontinuation of drug misuse striae can persist as white streaks (70).

**Conclusion**

There is a dearth of controlled clinical trials and long-term observations on the side-effects of AAS (and other APEDs) and our knowledge on adverse effects is based only on case reports and a few retrospective investigations. Strangely enough, medicine had turned a blind eye on APEDs. For a long time scientific medicine even negated positive effects by AAS on muscle mass and strength, as documented in a 1991 meta-
analysis concluding from a Medline search for publications (1966 to 1990) that there was no convincing evidence that AAS were increasing muscle power (97). This conclusion was partly based on the fact that AAS doses used in academic studies were in the range of therapeutic replacement doses, far below the doses and combinations used in the real doping world. Bhasin et al. (98) were among the first to apply testosterone doses exceeding clinical replacement levels in their controlled studies and demonstrated a clear positive effect on muscle strength. However, performing prospective randomized controlled trials (RCT) on short and long-term adverse effects of AAS and other APEDs is impossible because 1.) supraphysiological doses, long-term duration and the combination of AAS with other drugs would be unethical, 2.) some AAS are not licenced drugs with no or only limited toxicology available, 3.) high-risk behaviour and life-style factors of the doping individuals cannot be recreated in the setting of a RCT, 4.) AAS may be hidden in food supplements and not easily accessible, and 5.) studies extending over years and decades are unattractive to researchers (19). Under current circumstances the recent US Endocrine Society's Scientific Statement Task Force (SSTF) recommends 1.) establishing prospective observational cohort studies (registries) to determine long-term health effects of AAS and APED use, 2.) establishing epidemiologic surveys to determine the prevalence of AAS and APED use in the general population, 3.) performing human and animal studies to determine the mechanisms by which APEDs exert their adverse effects and 4.) conducting randomized trials of various therapeutic strategies to treat adverse effects of AAS and APED use (19). In addition, since athletes, bodybuilders and fitness studio customers appear to have only vague knowledge of the side-effects of AAS which they often belittle in the light of the relatively few severe long-term
problems in relation to the vast number of AAS abusers (99), more education of consumers, as well as athletic educators and health care providers about the possible sequelae of AAS and APED abuse is mandatory to prevent negative long-term effects (100).

Disclosures
The authors have not received any financial support for writing this manuscript and declare no conflict of interest.

Acknowledgement
Language editing of the manuscript by Susan Nieschlag MA is gratefully acknowledged.

References
6 Krug O, Thomas A, Walpurgis K, Piper T, Sigmund G, Schänzer W, Laussmann T,


64 Braunstein GD. Safety of testosterone treatment in postmenopausal women. *Fertility and Sterility* 2007 **88** 1-16.


80 De Gooyer ME, Oppers-Tiemissen HM, Leysen D, Verheul HA, Kloosterboer HJ.
Tibolone is not converted by human aromatase to 7alpha-ethynylestradiol (7alpha-MEE): analyses with sensitive bioassays for estrogens and androgens and with LC-MSMS. Steroids 2008 68 235-243.


**Legend to the figures:**

**Figure 1** Anabolic androgenic steroids (AAS) detected most often in international doping control tests. 1: AAS that can be aromatized, 2: AAS that are or can be 5alpha-reduced 3: AAS with the liver-toxic 17alpha-alkylation (adapted from 1).

**Figure 2** Sperm concentrations in 41 bodybuilders currently using anabolic steroids, 3-14 weeks ago or > 14 weeks ago (upper part) and in 41 drug-free volunteers (lower part). The bars represent sperm concentrations from individual body-builders (upper panel) and from normal volunteers (lower panel). The red lines indicate a concentration of 20 million/ml as lower limit of normal (modified from 28).
Anabolic androgenic steroids (AAS) constitute 87% of illegal appearance and performing enhancing drugs (APED) confiscated by customs or on the black market in Germany 2010-2013; more than half are testosterone (T) preparations (data from 6).

<table>
<thead>
<tr>
<th>AAS</th>
<th>kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testosterone (T)</td>
<td>145.5</td>
</tr>
<tr>
<td>Metandienone</td>
<td>34.3</td>
</tr>
<tr>
<td>Nandrolone</td>
<td>26.6</td>
</tr>
<tr>
<td>Trenbolone</td>
<td>15.9</td>
</tr>
<tr>
<td>Stanozolol</td>
<td>10.3</td>
</tr>
<tr>
<td>Oral turinabol</td>
<td>10.0</td>
</tr>
<tr>
<td>Boldenone</td>
<td>8.9</td>
</tr>
<tr>
<td>Drostanolone</td>
<td>4.7</td>
</tr>
<tr>
<td>Oxandrolone</td>
<td>1.2</td>
</tr>
<tr>
<td>Oxymetholone</td>
<td>1.2</td>
</tr>
<tr>
<td>Methenolone</td>
<td>0.3</td>
</tr>
<tr>
<td>Methyldrostanolone</td>
<td>0.3</td>
</tr>
<tr>
<td><strong>In total</strong></td>
<td><strong>259.3</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>T preparations</th>
<th>kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>T enanthate</td>
<td>81.9</td>
</tr>
<tr>
<td>T propionate</td>
<td>32.1</td>
</tr>
<tr>
<td>T isocaproate</td>
<td>18.0</td>
</tr>
<tr>
<td>T decanoate</td>
<td>5.5</td>
</tr>
<tr>
<td>T cypionate</td>
<td>5.2</td>
</tr>
<tr>
<td>T phenylpropionate</td>
<td>1.5</td>
</tr>
<tr>
<td>T (unesterified)</td>
<td>1.3</td>
</tr>
<tr>
<td><strong>In total</strong></td>
<td><strong>145.5</strong></td>
</tr>
</tbody>
</table>
Table 2

**Side effects of high-dose steroids on reproductive and sexual functions/organs**

**In men**
- Suppressions of gonadotropins
- Suppressions of spermatogenesis
- Decrease of testis volume
- Infertility
- Baldness
- Gynecomastia
- Loss of libido
- Erectile dysfunction
- Profuse sweating
- Striae distensae
- Acne
- Global effect: Anabolic Steroid Induced Hypogonadism (ASIH)

**In women**
- Suppressions of gonadotropins
- Anovulation & amenorrhoe
- Dysmenorrhoe
- Infertility
- Hirsutism & alopecia
- Atrophy of the breasts
- Striae distensae
- Acne
- Clitoris hypertrophy
- Dysphonia
- (Irreversible) deepening of the voice
Fig. 1

Boldenone 1,2  Clostebol  Dihydrotestosterone  Dehydrochloromethyltestosterone 3  Drostanolone  Fluoxymesterone 2,3

Formebolone 2,3  Mesterolone  Metandienone 1,2,3  Methenolone 3  Methyltestosterone 3  Nortestosterone 1,2

Oxandrolone 3  Oxymetholone 3  Stanozolol 3  Testosterone 1,2  Trenbolone
Fig. 2

AAS > 14 weeks ago

AAS 3 - 14 weeks ago

Current AAS users

Normal volunteers

Sperm concentration (millions/mL)